Arcutis Biotherapeutics, Inc. (ARQT)

From the record

Arcutis Biotherapeutics, Inc.'s filings since 2019 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Arcutis Biotherapeutics, Inc.'s 6 filed years say what it did: it rose in 3 of 3 years; it never fell from a peak; net income was positive in 0 of 6 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Arcutis Biotherapeutics, Inc. lost about 9 cents for every dollar of shareholders' money, and gross profitability: its products earned about 77 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 56 cents per dollar of assets, and net share issuance: its share count grew 5.2% over the year (the filed statements).

From the record

Arcutis Biotherapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $372 million in fiscal 2025 ranks in the top 22% by size; a net margin of -4.3% ranks in the top 26%; revenue growth of 365.4% a year over the last 3 filed years ranks in the top 4% (its annual reports).

From the record

Arcutis Biotherapeutics, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 15 officers and directors filing in the last fifteen months have been on the record a median of 5.2 years (bottom 39%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 49%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Arcutis Biotherapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $43 million against debt of $109 million leaves -15.2% of its assets as net cash, bottom 9% of its family; cash from operations less capital spending is -1.7% of revenue (top 30%); a gross margin of 90.1% (top 14%); research spending of 20.7% of revenue (bottom 27%) (its annual report).

From the record

Arcutis Biotherapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 123.5% (top 15%); research spending grew -25% a year (bottom 16%); capital spending grew 27.2% a year (top 21%) (its annual reports). Arcutis Biotherapeutics, Inc. reported 4 product lines in fiscal 2025: ZORYVE Foam at $182 million (49%), ZORYVE Cream0.3 at $121 million (33%), ZORYVE Cream0.15 at $68 million (18%), and 1 more; 3 of 3 grew against the year before (its annual report).

From the record

Arcutis Biotherapeutics, Inc.'s newest year against its own record: revenue of $372 million in fiscal 2025 came in 66.7% below the $1.1 billion its prior three years' pace pointed to (bottom 13% of its family); net income of $16 million against a prior three-year average of $238 million (top 17%); a net margin of -4.3% against losses larger than its revenue before (top 11%) (its annual reports).